15hon MSN
Novo’s Wegovy and Lilly’s Zepbound recommended in Europe as first-line obesity treatments
A leading European medical group announced a new framework for treating obesity on Thursday, recommending Novo’s (NVO) semaglutide and Lilly’s (NYSE:LLY) tirzepatide, marketed as Wegovy and Zepbound, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback